Demand for anti-superbug remedies boosts sales outlook at Teva supplier Venus Remedies; Recipharm grabs manufacturing deal from Astimex Pharma;

> Peru's tougher GMP requirements on drugmakers have stymied the approval of new drugs in the country. Article

> Venus Remedies, an India-based supplier of meds for Teva Pharmaceutical Industries ($TEVA), expects 15% growth in sales over the next two years in part because of demand for anti-bacterial drugs against superbugs. Report

> Recipharm sealed a development manufacturing deal with Astimex Pharma. Item

> Under a deal announced Monday, Ark Therapeutics Group will manufacture and provide Lymfactin to Laurantis Pharma. Report

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.